Cargando…

COVID-19 and Vaccination in the Setting of Neurologic Disease: An Emerging Issue in Neurology

The coronavirus disease 2019 (COVID-19) pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has left many unanswered questions for patients with neurologic disorders and the providers caring for them. Elderly and immunocompromised patients are at increased risk for se...

Descripción completa

Detalles Bibliográficos
Autores principales: Marsh, Elisabeth B., Kornberg, Michael, Kessler, Kevin, Haq, Ihtsham, Patel, Anup D., Nath, Avindra, Schierman, Becky, Jones, Lyell K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8575134/
https://www.ncbi.nlm.nih.gov/pubmed/34326180
http://dx.doi.org/10.1212/WNL.0000000000012578
_version_ 1784595613699014656
author Marsh, Elisabeth B.
Kornberg, Michael
Kessler, Kevin
Haq, Ihtsham
Patel, Anup D.
Nath, Avindra
Schierman, Becky
Jones, Lyell K.
author_facet Marsh, Elisabeth B.
Kornberg, Michael
Kessler, Kevin
Haq, Ihtsham
Patel, Anup D.
Nath, Avindra
Schierman, Becky
Jones, Lyell K.
author_sort Marsh, Elisabeth B.
collection PubMed
description The coronavirus disease 2019 (COVID-19) pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has left many unanswered questions for patients with neurologic disorders and the providers caring for them. Elderly and immunocompromised patients are at increased risk for severe symptoms due to COVID-19, and the virus may increase symptoms of underlying neurologic illness, particularly for those with substantial bulbar and respiratory weakness or other neurologic disability. Emerging SARS-CoV-2 vaccines offer substantial protection from symptomatic infection, but both patients and providers may have concerns regarding theoretical risks of vaccination, including vaccine safety and efficacy in the context of immunotherapy and the potential for precipitating or exacerbating neurologic symptoms. In this statement on behalf of the Quality Committee of the American Academy of Neurology, we review the current literature, focusing on COVID-19 infection in adults with neurologic disease, in order to elucidate risks and benefits of vaccination in these individuals. Based on existing evidence, neurologists should recommend COVID-19 vaccination to their patients. For those patients being treated with immunotherapies, attention should be paid to timing of vaccination with respect to treatment and the potential for an attenuated immune response.
format Online
Article
Text
id pubmed-8575134
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-85751342021-11-09 COVID-19 and Vaccination in the Setting of Neurologic Disease: An Emerging Issue in Neurology Marsh, Elisabeth B. Kornberg, Michael Kessler, Kevin Haq, Ihtsham Patel, Anup D. Nath, Avindra Schierman, Becky Jones, Lyell K. Neurology Review The coronavirus disease 2019 (COVID-19) pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has left many unanswered questions for patients with neurologic disorders and the providers caring for them. Elderly and immunocompromised patients are at increased risk for severe symptoms due to COVID-19, and the virus may increase symptoms of underlying neurologic illness, particularly for those with substantial bulbar and respiratory weakness or other neurologic disability. Emerging SARS-CoV-2 vaccines offer substantial protection from symptomatic infection, but both patients and providers may have concerns regarding theoretical risks of vaccination, including vaccine safety and efficacy in the context of immunotherapy and the potential for precipitating or exacerbating neurologic symptoms. In this statement on behalf of the Quality Committee of the American Academy of Neurology, we review the current literature, focusing on COVID-19 infection in adults with neurologic disease, in order to elucidate risks and benefits of vaccination in these individuals. Based on existing evidence, neurologists should recommend COVID-19 vaccination to their patients. For those patients being treated with immunotherapies, attention should be paid to timing of vaccination with respect to treatment and the potential for an attenuated immune response. Lippincott Williams & Wilkins 2021-10-12 /pmc/articles/PMC8575134/ /pubmed/34326180 http://dx.doi.org/10.1212/WNL.0000000000012578 Text en Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
spellingShingle Review
Marsh, Elisabeth B.
Kornberg, Michael
Kessler, Kevin
Haq, Ihtsham
Patel, Anup D.
Nath, Avindra
Schierman, Becky
Jones, Lyell K.
COVID-19 and Vaccination in the Setting of Neurologic Disease: An Emerging Issue in Neurology
title COVID-19 and Vaccination in the Setting of Neurologic Disease: An Emerging Issue in Neurology
title_full COVID-19 and Vaccination in the Setting of Neurologic Disease: An Emerging Issue in Neurology
title_fullStr COVID-19 and Vaccination in the Setting of Neurologic Disease: An Emerging Issue in Neurology
title_full_unstemmed COVID-19 and Vaccination in the Setting of Neurologic Disease: An Emerging Issue in Neurology
title_short COVID-19 and Vaccination in the Setting of Neurologic Disease: An Emerging Issue in Neurology
title_sort covid-19 and vaccination in the setting of neurologic disease: an emerging issue in neurology
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8575134/
https://www.ncbi.nlm.nih.gov/pubmed/34326180
http://dx.doi.org/10.1212/WNL.0000000000012578
work_keys_str_mv AT marshelisabethb covid19andvaccinationinthesettingofneurologicdiseaseanemergingissueinneurology
AT kornbergmichael covid19andvaccinationinthesettingofneurologicdiseaseanemergingissueinneurology
AT kesslerkevin covid19andvaccinationinthesettingofneurologicdiseaseanemergingissueinneurology
AT haqihtsham covid19andvaccinationinthesettingofneurologicdiseaseanemergingissueinneurology
AT patelanupd covid19andvaccinationinthesettingofneurologicdiseaseanemergingissueinneurology
AT nathavindra covid19andvaccinationinthesettingofneurologicdiseaseanemergingissueinneurology
AT schiermanbecky covid19andvaccinationinthesettingofneurologicdiseaseanemergingissueinneurology
AT joneslyellk covid19andvaccinationinthesettingofneurologicdiseaseanemergingissueinneurology
AT covid19andvaccinationinthesettingofneurologicdiseaseanemergingissueinneurology